Biocryst Pharmaceuticals Inc. (BCRX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Biocryst Pharmaceuticals’s revenue went from $26M in fiscal 2016 to $875M in fiscal 2025, growth of about 47.6% a year.
Net income in fiscal 2025 was $264M, a net margin of 30.2%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $962M and net income -$360M.
Free cash flow was $345M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 296486% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $962M | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M |
| Gross profit | $941M | $856M | $438M | $327M | $264M | $150M | $16M | $45M | — | $24M | $24M |
| Operating income | -$289M | $341M | -$3M | -$104M | -$148M | -$178M | -$175M | -$99M | -$94M | -$57M | -$49M |
| Net income | -$360M | $264M | -$89M | -$227M | -$247M | -$184M | -$183M | -$109M | -$101M | -$66M | -$55M |
| EPS (diluted) | $-1.28 | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-940.00 | $-980.00 | $-780.00 | $-750.00 |
| R&D | $211M | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M |
| Revenue growth | — | +94.1% | +36.0% | +22.4% | +72.3% | +782.4% | −63.5% | +136.5% | −18.0% | −4.4% | −45.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $367M | $347M | -$52M | -$95M | -$162M | -$142M | -$135M | -$90M | -$93M | -$41M | -$53M |
| Capital spending | -$2M | -$2M | -$1M | -$2M | -$1M | -$2M | -$514000 | -$343000 | -$366000 | -$328000 | -$5M |
| Free cash flow | $366M | $345M | -$53M | -$97M | -$163M | -$145M | -$136M | -$90M | -$93M | -$41M | -$59M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $69M | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $275M | $321M | $389M | $424M | $508M | $300M | $136M | $104M | $114M | $55M |
| Debt | — | $9M | $324M | $313M | $237M | $306M | $155M | $50M | $30M | $29M | $28M |
| Equity | — | -$119M | -$476M | -$456M | -$295M | -$107M | -$19M | $38M | $49M | $84M | $2M |
| Total assets | — | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M |
| Shares (diluted) | 268M | 219M | 207M | 192M | 186M | 179M | 167M | 116M | 0M | 0M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 97.9% | 97.8% | 97.3% | 98.7% | 97.6% | 95.4% | 91.3% | 92.4% | — | 95.5% | 91.3% |
| Operating margin | -30.1% | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -228.0% | -184.4% |
| Net margin | -37.4% | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | -261.2% | -209.2% |
| FCF margin | 38.0% | 39.4% | -11.8% | -29.4% | -60.3% | -92.0% | -761.4% | -184.1% | -450.0% | -164.7% | -222.8% |
| ROIC | — | — | — | — | — | -70.6% | -129.0% | -112.7% | -93.9% | -40.3% | -128.8% |
| ROE | — | -221.5% | 18.7% | 49.7% | 83.9% | 172.0% | 949.1% | -284.7% | -205.7% | -78.5% | -3494.6% |
Frequently asked questions
What is Biocryst Pharmaceuticals’s annual revenue?
$875M in fiscal 2025 and $962M over the twelve months to September 30, 2026.
How much profit does Biocryst Pharmaceuticals make?
Net income was $264M in fiscal 2025 (net margin 30.2%).
Is Biocryst Pharmaceuticals’s revenue growing?
Yes: revenue rose 94.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.